Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/15/2025

Management of Taxane-Induced Numbness

Assessment and Monitoring

  • Peripheral sensory neuropathy related to taxanes is dose-dependent and more frequent in patients with comorbidities such as diabetes and older age 2
  • Clinical identification of residual neuropathy intensity and impact on quality of life should be included in follow-up 2
  • Self-reporting questionnaires dedicated to neuropathy can be used (e.g., CIPN subscale of the EORTC QOL Questionnaire or Module NTX of the FACT questionnaire) 2

Treatment Algorithm for Taxane-Induced Numbness

  • Duloxetine is the recommended first-line treatment option, demonstrating significant improvement in both pain (P = .04) and numbness (P = .03) symptoms in patients with chemotherapy-induced peripheral neuropathy 1
  • Pregabalin may be considered as an alternative option, with some evidence suggesting benefit in reducing CIPN symptoms, though studies show mixed results 1
  • Gabapentin may be considered for neuropathic symptoms, though evidence is limited 2
  • Venlafaxine can be considered for neuropathy symptoms, particularly if depression is also present 2

Non-Pharmacological Approaches

  • Home-based, moderate-intensity walking and resistance exercise programs have shown benefit in reducing CIPN symptoms including numbness and tingling 3
  • Exercise significantly reduced symptoms of hot/coldness in hands/feet (P = .045) and showed trends toward reducing numbness and tingling 3
  • Acupuncture may provide some relief for neuropathy symptoms, though evidence is mixed 2, 4
  • Supportive care measures, including physical activity and physiotherapy, patient education regarding adequate footwear, referral to podiatrists for foot care, and support in daily activities, can be beneficial 2

Important Considerations and Caveats

  • Symptoms may persist long-term after treatment completion (15-40% after taxane chemotherapy) and can impact quality of life and function 2
  • Vitamin B supplementation can be discussed, though evidence for efficacy is limited 2
  • Acetyl-L-carnitine is not recommended for prevention or treatment of CIPN due to evidence of harm 4
  • For patients with severe symptoms affecting daily function, referral to a neurologist may be appropriate for further investigation 2
  • Monitor for and prevent comorbidities that may worsen neuropathy symptoms 2